Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 17 of 46

Summary of Study Characteristics Evaluated in the Effectiveness Review: PICOTS

Development of clinical studies of effectiveness of medical interventions is guided by the PICOTS (population, interventions, comparators, outcomes, timing, and setting) framework. These items are critical elements that will help to answer important clinical questions. In the CER, the clinical study literature was reviewed and summarized by using the PICOTS framework. The evidence concerning the outcomes identified here was examined in detail, and strength-of-evidence determinations were made only for these key outcomes.

Population: Individuals 18 years or younger, with a diagnosis of juvenile idiopathic (JIA), rheumatoid (JRA), or chronic (JCA) arthritis

  • JIA = International League of Associations for Rheumatology (ILAR)
  • JRA = American College of Rheumatology (ACR)
  • JCA = European League Against Rheumatism (EULAR)

Interventions: Biologic and nonbiologic DMARDs
Comparators: Conventional treatment, meaning NSAIDs and intra-articular corticosteroids, with or without methotrexate or another DMARD
Outcomes: Intermediate and long-term disease status, health status, inflammation markers, and radiographic progression
Timing: Intervention period of at least 3 months
Setting: Any setting for treatment of JIA